Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk
DOI: https://doi.org/10.7175/cmi.v6i2S.1138
Abstract
Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological response after one month of treatment.After about 3 months the patient presented a complete cytogenetic response and after six months major molecular response (MR3). At nine months of treatment the patient presented a complete molecular response (MR4).
Keywords
Chronic myeloid leukemia; Optimal response; Nilotinib
Full Text
Statistics
Abstract: 455 viewsPDF: 347 views
Refbacks
- There are currently no refbacks.